Merrimack Pharmaceuticals
Merrimack Pharmaceuticals discovers, designs and develops therapies for the treatment of diseases in the areas of autoimmunity and cancer.
Launch date
Employees
Market cap
$224m
Enterprise valuation
($20m) (Public information from May 2024)
Share price
$15.13 MACK
Cambridge Massachusetts (HQ)
Financials
Estimates*
| USD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| EBITDA | (78.5m) | (63.4m) | (23.9m) | (5.2m) | (2.8m) | (2.6m) | (2.3m) |
| Profit | 472m | (40.5m) | (17.3m) | (3.0m) | (2.5m) | (1.5m) | (1.2m) |
| EV / EBITDA | -0.6x | 0.1x | -1.1x | -15.2x | -13.8x | -51.2x | -74.8x |
| R&D budget | 67.3m | 50.0m | 11.1m | - | 11.1m | 11.1m | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | $15.0m | Series B | |
N/A | Series B | ||
| N/A | $18.3m | Series C | |
$28.0m | Series D | ||
| N/A | $28.3m | Series D | |
$65.0m | Series E | ||
| N/A | $35.0m | Series F | |
| N/A | $2.4m | Grant | |
$77.0m | Growth Equity VC | ||
| N/A | N/A | IPO | |
$25.0m | Post IPO Debt | ||
| Total Funding | $269m | ||